P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment

Real World ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutated ◽

Inhibitor Treatment

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

Case Medical Research ◽

10.31525/ct1-nct04007835 ◽

2019 ◽

Author(s):

Keyword(s):

Tyrosine Kinase ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Egfr Tki

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Line Treatment ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor

Annals of Oncology ◽

10.1093/annonc/mdx380.080 ◽

2017 ◽

Vol 28 ◽

pp. v493 ◽

Cited By ~ 2

Author(s):

K. Park ◽

F. Ciardiello ◽

T. Hida ◽

W. Lim ◽

C-C. Lin ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Molecular and Clinical Oncology ◽

10.3892/mco.2018.1550 ◽

2018 ◽

Author(s):

Ming‑Szu Hung ◽

Yu‑Hung Fang ◽

Yu‑Ching Lin ◽

Jr‑Hau Lung ◽

Meng‑Jer Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Associated Factors ◽

Kinase Inhibitor ◽

Egfr Mutations ◽

First Line ◽

Egfr Tyrosine Kinase

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2100 ◽

2020 ◽

Vol 31 (11) ◽

pp. 1536-1544

Author(s):

V.A. Papadimitrakopoulou ◽

T.S. Mok ◽

J.-Y. Han ◽

M.-J. Ahn ◽

A. Delmonte ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Tyrosine Kinase ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Overall Survival Analysis ◽

Egfr T790m

Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience

Lung Cancer ◽

10.1016/s0169-5002(21)00300-7 ◽

2021 ◽

Vol 156 ◽

pp. S42-S43

Author(s):

Sean Dulloo ◽

Manar Almusarhed ◽

Ryan Chen ◽

Oyeyemi Akala ◽

Balaji Varadhan ◽

...

Keyword(s):

Tyrosine Kinase ◽

Real World ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancers ◽

2Nd Generation ◽

Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

EJNMMI Research ◽

10.1186/s13550-018-0376-6 ◽

2018 ◽

Vol 8 (1) ◽

Cited By ~ 1

Author(s):

R. Iqbal ◽

◽

G. M. Kramer ◽

V. Frings ◽

E. F. Smit ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Tumour Response ◽

Imaging Biomarker ◽

Egfr Tyrosine Kinase ◽

Nsclc Patients ◽

Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program

Annals of Oncology ◽

10.1093/annonc/mdx091.030 ◽

2017 ◽

Vol 28 ◽

pp. ii40

Author(s):

M. Ehmann ◽

L. Wannesson ◽

M. Pless ◽

M. Früh ◽

O. Gautschi ◽

...

Keyword(s):

Tyrosine Kinase ◽

Retrospective Analysis ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors

Lung Cancer ◽

10.1016/j.lungcan.2010.11.007 ◽

2011 ◽

Vol 73 (2) ◽

pp. 195-202 ◽

Cited By ~ 59

Author(s):

Qiong Zhao ◽

Jianzhong Shentu ◽

Nong Xu ◽

Jianya Zhou ◽

Guangdie Yang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Nsclc ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.07.012 ◽

2018 ◽

Vol 13 (11) ◽

pp. e232-e234 ◽

Cited By ~ 10

Author(s):

Etienne Giroux-Leprieur ◽

Coraline Dumenil ◽

Thierry Chinet

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽